Fungizone

Cerebral Cryptococcosis, Histoplasmosis, Coccidioidomycosis + 25 more

Treatment

28 FDA approvals

20 Active Studies for Fungizone

What is Fungizone

Amphotericin B

The Generic name of this drug

Treatment Summary

Amphotericin B is an antifungal medication used to treat a variety of fungal infections. It is effective against several species of fungi, such as Histoplasma capsulatum, Coccidioides immitis, and Candida species, among others. There are some species that are less susceptible to the drug, such as Pseudallescheria boydii and Fusarium sp., while Candida albicans is usually quite responsive. Amphotericin B has no effect on bacteria, rickettsiae, or viruses.

Fungizone

is the brand name

image of different drug pills on a surface

Fungizone Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Fungizone

Amphotericin B

1966

10

Approved as Treatment by the FDA

Amphotericin B, otherwise called Fungizone, is approved by the FDA for 28 uses like severe Fungal infection caused by Basidiobolus spp. and severe Fungal infection caused by Conidiobolus spp. .

severe Fungal infection caused by Basidiobolus spp.

severe Fungal infection caused by Conidiobolus spp.

severe Mucocutaneous leishmaniasis

severe Fungal infection caused by sporotrichosis spp.

severe North American blastomycosis

Histoplasmosis

Leishmaniasis, Visceral

Sporotrichosis

Mycoses

Cryptococcosis

Febrile Neutropenia

failed previous amphotericin B treatment

Used to treat failed previous amphotericin B treatment in combination with DL-dimyristoylphosphatidylcholine

severe Histoplasmosis

Visceral Leishmaniasis

severe Cryptococcosis

severe Systemic candidiasis

Mucocutaneous Leishmaniasis

Meningitis, Cryptococcal

Febrile Neutropenia

Leishmaniasis, Cutaneous

Gilchrist Disease

Coccidioidomycosis

Systemic candidiasis

Leishmaniasis, Mucocutaneous

Mycoses

Cerebral Cryptococcosis

HIV

Invasive Fungal Infections

Effectiveness

How Fungizone Affects Patients

Amphotericin B is an anti-fungal medicine that works in a laboratory setting against many different types of fungi, including Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus. It is usually effective against Candida albicans, but may be less effective against other species. It does not work against bacteria, rickettsiae, or viruses.

How Fungizone works in the body

Amphotericin B is a medication that works by attaching to special molecules in the cell membrane of certain fungi. This creates a hole in the membrane, causing the cell to leak and die. Ergosterol, a molecule found in fungal cell membranes, is the primary target of Amphotericin B. By binding to ergosterol, Amphotericin B can stop the fungus from reproducing and ultimately kill it.

When to interrupt dosage

The suggested dosage of Fungizone is contingent upon the diagnosed condition, including Aspergillosis, grave Cryptococcosis and grave Mucocutaneous leishmaniasis. The sum of dosage fluctuates, in accordance with the approach of delivery outlined in the table beneath.

Condition

Dosage

Administration

Cerebral Cryptococcosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Tuberculosis, Osteoarticular

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Aspergillosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Gilchrist Disease

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Coccidioidomycosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Systemic candidiasis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Mycoses

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Aspergillosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Cystitis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Histoplasmosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Leishmaniasis, Cutaneous

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Mycoses

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Sporotrichosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

failed previous amphotericin B treatment

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Leishmaniasis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Cryptococcosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Histoplasmosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Coccidioidomycosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Cryptococcosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Endophthalmitis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for solution - Intravenous, Powder, for solution, Powder, for suspension, Powder, for suspension - Intravenous, Suspension - Intravenous, Suspension, Injection, Injection - Intravenous, Lotion - Topical, Cream - Topical, Topical

Warnings

There are 20 known major drug interactions with Fungizone.

Common Fungizone Drug Interactions

Drug Name

Risk Level

Description

Cyclosporine

Major

Amphotericin B may increase the nephrotoxic activities of Cyclosporine.

Neomycin

Major

The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Neomycin.

Tenofovir

Major

Amphotericin B may increase the nephrotoxic activities of Tenofovir.

Tenofovir alafenamide

Major

Amphotericin B may increase the nephrotoxic activities of Tenofovir alafenamide.

Tenofovir disoproxil

Major

Amphotericin B may increase the nephrotoxic activities of Tenofovir disoproxil.

Fungizone Toxicity & Overdose Risk

The lowest toxic dose of amphotericin B for rats has been found to be greater than 5gm/kg. Overdosing on amphotericin B can lead to cardiac and respiratory arrest.

image of a doctor in a lab doing drug, clinical research

Fungizone Novel Uses: Which Conditions Have a Clinical Trial Featuring Fungizone?

10 active trials are currently in progress to investigate the potential of Fungizone to address Meningitis, Fungal Histoplasmosis and Fungal Infections.

Condition

Clinical Trials

Trial Phases

Tuberculosis, Osteoarticular

0 Actively Recruiting

Coccidioidomycosis

0 Actively Recruiting

Cerebral Cryptococcosis

1 Actively Recruiting

Phase 2, Phase 3

Mycoses

0 Actively Recruiting

Aspergillosis

0 Actively Recruiting

Cryptococcosis

0 Actively Recruiting

Histoplasmosis

0 Actively Recruiting

Meningitis, Fungal

0 Actively Recruiting

Histoplasmosis

1 Actively Recruiting

Phase 3

Systemic candidiasis

3 Actively Recruiting

Phase 3, Phase 2

Febrile Neutropenia

3 Actively Recruiting

Phase 2, Not Applicable

Cryptococcosis

0 Actively Recruiting

talaromycosis

0 Actively Recruiting

Leishmaniasis, Cutaneous

0 Actively Recruiting

Invasive Fungal Infections

3 Actively Recruiting

Phase 3, Phase 2

Endophthalmitis

0 Actively Recruiting

Mycoses

0 Actively Recruiting

Leishmaniasis, Mucocutaneous

0 Actively Recruiting

Aspergillosis

0 Actively Recruiting

Gilchrist Disease

0 Actively Recruiting

Fungizone Reviews: What are patients saying about Fungizone?

5

Patient Review

3/25/2008

Fungizone for Fungal Meningitis caused by Cryptococcus

I was treated with this medication for 10 days. I had some side effects, but they were manageable. The staff at University Hospital in Birmingham, AL were great and really helped me through the process.

3

Patient Review

3/16/2010

Fungizone for Osteoporosis

This treatment really helped me. I'm grateful for modern medicine.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about fungizone

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is amphotericin same as fungizone?

"Amphotericin B is a drug used to prevent and treat deep, serious fungal infections. The usual formulation of amphotericin B is amphotericin B deoxycholate (Fungizone®)."

Answered by AI

How do you administer fungizone?

"Fungizone should be administered intravenously over a period of 2-6 hours, gradually increasing the initial daily dose of 0.25 mg/kg of body weight to 1.0 mg/kg, depending on individual response and tolerance."

Answered by AI

Is fungizone an antibiotic?

"Fungizone is an antifungal antibiotic that is used to treat serious fungal infections. It is usually given after other antifungal antibiotics have been unsuccessful."

Answered by AI

What is fungizone used for?

"Fungizone is a drug used to treat fungal infections. It may be used alone or with other medications. Fungizone belongs to a class of drugs called antifungals."

Answered by AI

Clinical Trials for Fungizone

Image of George Washington University Emergency Department in Washington D.C., United States.

Decision Support Tool for HIV Prevention

18+
All Sexes
Washington D.C., United States

This project will explore the development of a personalized decision support tool to assist with pre-exposure prophylaxis (PrEP) initiation and persistence among patients identified in the emergency department (ED) and urgent care settings as PrEP eligible. First, the investigators will use a sequence of validated implementation science methodologies to develop and validate a decision support tool designed to optimize PrEP persistence by strengthening self-efficacy by addressing the multifaceted medical and social needs of the individual patient. The investigators will then test the preliminary effectiveness of this tool through a pilot stepped wedge implementation trial in two EDs and an urgent care in Baltimore, MD and Washington, DC among 120 PrEP eligible patients to determine PrEP initiation, linkage to care, persistence, and adherence rates.

Phase 1
Waitlist Available

George Washington University Emergency Department (+1 Sites)

Image of The University of Alabama at Birmingham in Birmingham, United States.

Behavioral vs Mindfulness Treatments for Insomnia in HIV

50 - 99
All Sexes
Birmingham, AL

The goal of this clinical trial is to examine the effects of a telephone-delivered Brief Behavioral Treatment Insomnia (BBTI) versus a Brief Mindfulness Treatment (BMT) on cognitive and sleep outcomes in older adults with HIV. The main questions it aims to answer are: What are the effects of BBTI vs BMT on self-reported and observed sleep outcomes in older adults with HIV and insomnia up to 1-year post-intervention? What are the effects of BBTI vs BMT on self-reported and observed cognitive comes in older adults with HIV and insomnia up to 1-year post-intervention? What is the association between Alzheimer's Disease biomarkers and sleep and cognitive outcomes in older adults with HIV receiving BBTI vs BMT? Participants will: * Complete 4 weeks of telephone-delivered BBTI or BMT * Attend baseline, post-intervention, and 1-year post in-person visits for sleep and cognitive assessments * Have blood collected at all three time points

Waitlist Available
Has No Placebo

The University of Alabama at Birmingham (+1 Sites)

Dr. Shameka L Cody, PhD, AGNP-C, PMHNP-BC, FAAN

Image of University of Minnesota in Minneapolis, United States.

LAmB and Posaconazole for Histoplasmosis

18+
All Sexes
Minneapolis, MN

The purpose of the study is threefold: 1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to severe histoplasmosis. 2. Assess the safety and efficacy of oral posaconazole 300mg delayed-release tablets three times daily for two days then once daily for consolidation therapy compared to SOC oral itraconazole 200 mg capsules three times daily for three days then twice daily in moderate to severe histoplasmosis 3. Assess the safety and efficacy of 6 months of consolidation therapy compared to the SOC 12 months of consolidation therapy in persons with HIV on appropriate antiretroviral therapy.

Phase 3
Waitlist Available

University of Minnesota

Nathan Bahr, MD

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL

The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.

Phase < 1
Waitlist Available

University of Alabama at Birmingham

Have you considered Fungizone clinical trials?

We made a collection of clinical trials featuring Fungizone, we think they might fit your search criteria.
Go to Trials
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC

This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.

Phase 1
Recruiting

University of North Carolina

Cynthia L. Gay, MD

Image of Center on Substance Use and Health in San Francisco, United States.

CHAMPION Intervention for Pre-exposure Prophylaxis Adherence

18 - 40
Male
San Francisco, CA

The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: * To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. * To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.

Waitlist Available
Has No Placebo

Center on Substance Use and Health

Glenn-Milo Santos, PhD, MPH

Have you considered Fungizone clinical trials?

We made a collection of clinical trials featuring Fungizone, we think they might fit your search criteria.
Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA

Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.

Phase 2
Waitlist Available

UCSF

Have you considered Fungizone clinical trials?

We made a collection of clinical trials featuring Fungizone, we think they might fit your search criteria.
Go to Trials